Anacor Pharmaceuticals, Inc. (ANAC) reported fourth quarter EPS of ($0.24) in the extended session Thursday, compared to the consensus estimate of ($0.60). Revenues increased nearly 13% from last year to $9.6 million. Analysts expected revenues of $4.73 million. The stock is currently up $2.38 to $50.90 on 680K shares.
For Q4/14, the biopharmaceutical firm reported research contracts revenue of $3.2 million, compared to $8.5 million for the comparable period in 2013. Research contracts revenue for full-year 2014 was $13.1 million compared to $17.2 million in 2013. R&D expenses for Q4 and full year 2014 were $17.8 million and $72.5 million, respectively.
On valuation measures, Anacor Pharmaceuticals Inc. shares, which currently have an average 3-month trading volume of 463,281.00 shares, trade at a trailing-12 P/E of 38.78, and a P/E to growth ratio of 1.31. The median Wall Street price target on the name is $43.00 with a high target of $50.00. Currently ticker boasts 4 ‘Buy’ endorsements, compared to 1 ’Hold’ and no ‘Sell’.
Profitability-wise, ANAC has a t-12 profit and operating margin of 275.11% and (420.68%), respectively. The $2.08 billion market cap company reported $191.6 million in cash in its most recent quarter.
ANAC currently prints a one year return of about 147% and a year-to-date return of around 55%.
Anacor Pharmaceuticals Inc., formerly known as AnaMax, Inc., is a Palo Alto, Calif.-based biopharmaceutical company focused on developing novel small-molecule therapeutics derived from its boron chemistry platform.